Aarti Drugs Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).

Due to this company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market.

USFDA had inspected the company’s API manufacturing facility at Plot No-E-22, MIDC, Tarapur, Maharashtra from 12th to 20th September 2024.

Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals.

The company’s consolidated net profit dropped 11.6% to Rs 35.01 crore on 6.7% decline in net sales to Rs 598.33 crore in Q2 FY25 over Q2 FY24.

Powered by Capital Market - Live News

Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra.

UFDA has determined that the inspection classification of this facility is “voluntary action indicated” (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).

Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 24 October 2024.

Powered by Capital Market - Live News